#GIM4 - Twitter Hashtag

Stephanie Graff, MD, FACP, FASCO @DrSGraff

over 4 years ago

For #bcsm #GIM4 @delmastro_lucia @matteolambe @OncoAlert 👉🏻 https://t.co/klJUj8uDM1

1

10

3

1

0

Stephanie Graff, MD, FACP, FASCO @DrSGraff

almost 5 years ago

TONIGHT 🗓 October 6, ⏰7 PM ET: @BrownUCancer #bcsm #gycsm Journal Club on @TwitterSpaces. Join us as we discuss #GIM4 - extended adjuvant endocrine therapy AND #KEYNOTE826 - pembrolizumab for recurrent cervical cancer 📕https://t.co/klJUj8d2nr 📗https://t.co/u4H4bejo2r

1

17

7

0

Paolo Tarantino

@PTarantinoMD

almost 5 years ago

@matteolambe @NicoleKuderer @ADesaiMD @stolaney1 @ErikaHamilton9 @prat_aleix @kevinpunie @JavierCortesMD @DrSGraff @PatelOncology @Alfdoc2 @StephenVLiu @delmastro_lucia @TheLancetOncol @OncoAlert My scientific passions for HER2+/TNBC surely biased the list, but I strongly agree on #GIM4: important and brilliantly conducted trial, for which @delmastro_lucia, you and all coauthors should be congratulated! 👏

0

11

0

Matteo Lambertini, MD PhD @matteolambe

almost 5 years ago

@NicoleKuderer @PTarantinoMD @ADesaiMD @stolaney1 @ErikaHamilton9 @prat_aleix @kevinpunie @JavierCortesMD @DrSGraff @PatelOncology @Alfdoc2 @StephenVLiu Agree except for #carboplatin (no more controversy) and #TULIP (no impact so far): I would definitively include here Italian academic research with #GIM4 trial led by @delmastro_lucia and published in @TheLancetOncol (OS benefit) clarifying how to extend adjuvant #ET @OncoAlert

1

17

1

0

Luca Arecco, MD @Lucarecco

almost 5 years ago

Online on @TheLancetOncol & presented #ESMO21 by Prof. @delmastro_lucia from @SanMartino_Ge @UniGenova the Italian #GIM4 study on extended adj tp with letrozole in postmenopausal pts w/ early #BC. ⬆️5% in 12y-DFS with 7/8 yr of adj ET ✅ Acceptable toxicity @OncoAlert @myESMO

1

17

5

0

Benedetta Conte @BenedettaConte5

almost 5 years ago

Practice-changing results of #GIM4 trial presented today by Prof Lucia Del Mastro. Extending adj ET to 7-8 years improves OVERALL SURVIVAL in HR+ #breastcancer

0

15

2

1

0

Marco Tagliamento @M_Tagliamento

almost 5 years ago

Results from the #GIM4 trial presented at #ESMO21 by @delmastro_lucia and concomitantly published in @TheLancetOncol. Congratulations for the effort in conducting such academic trial! @OncoAlert @matteolambe @Poggio_Fra @myESMO https://t.co/M8R9ODNm0z

M_Tagliamento's tweet photo. Results from the #GIM4 trial presented at #ESMO21 by @delmastro_lucia and concomitantly published in @TheLancetOncol.
Congratulations for the effort in conducting such academic trial!
@OncoAlert @matteolambe @Poggio_Fra @myESMO
https://t.co/M8R9ODNm0z https://t.co/QAT0AOrZhe

Matteo Lambertini, MD PhD @matteolambe

almost 5 years ago

Third oral abstract presentation in the early #BreastCancer session at #ESMO21: results of the #GIM4 trial showing that 2-3 years of #tamoxifen followed by 5 years of an aromatase inhibitor can be considered a very good option as adjuvant endocrine therapy @myESMO @OncoAlert

matteolambe's tweet photo. Third oral abstract presentation in the early #BreastCancer session at #ESMO21: results of the #GIM4 trial showing that 2-3 years of #tamoxifen followed by 5 years of an aromatase inhibitor can be considered a very good option as adjuvant endocrine therapy
@myESMO @OncoAlert https://t.co/kGFhDp5SFl

2

50

16

2

0

31

4

2

0

Erika Hamilton, MD, FASCO @ErikaHamilton9

almost 5 years ago

Monica Arnedos discusses #GIM4: ❓❓ Is the switch from tam the reason we see benefit? What about pts with upfront AI? 🔆DATA trial discordant but shorter f/u AND benefit from AI typically later @OncoAlert #bcsm #ESMO21

ErikaHamilton9's tweet photo. Monica Arnedos discusses #GIM4:

❓❓ Is the switch from tam the reason we see benefit? What about pts with upfront AI?

🔆DATA trial discordant but shorter f/u AND benefit from AI typically later

@OncoAlert #bcsm #ESMO21 https://t.co/F7p3YE2WVn

1

6

2

0

Francesca Poggio @Poggio_Fra

almost 5 years ago

Finally, @delmastro_lucia presented at #ESMO2021 results of the #GIM4 trial:5 years of letrozolo after 2-3y of tam can be considered a good option of adjuvant endocrine treatment. Very proud to be involved in!@myESMO @matteolambe @OncoAlert @SanMartino_Ge

Matteo Lambertini, MD PhD @matteolambe

almost 5 years ago

Third oral abstract presentation in the early #BreastCancer session at #ESMO21: results of the #GIM4 trial showing that 2-3 years of #tamoxifen followed by 5 years of an aromatase inhibitor can be considered a very good option as adjuvant endocrine therapy @myESMO @OncoAlert

2

50

16

2

0

19

3

1

0

Matteo Lambertini, MD PhD @matteolambe

almost 5 years ago

Third oral abstract presentation in the early #BreastCancer session at #ESMO21: results of the #GIM4 trial showing that 2-3 years of #tamoxifen followed by 5 years of an aromatase inhibitor can be considered a very good option as adjuvant endocrine therapy @myESMO @OncoAlert

2

50

16

2

0

Erika Hamilton, MD, FASCO @ErikaHamilton9

almost 5 years ago

Lucia Del Mastro presents #GIM4- ph III of extended letrozole for adj post-meno pts after 2-3 yrs tam: ❇️ improved DFS by 5% ✴️ 4% improvement in OS For post-meno pts that get tam upfront, 7-8 years total w/ AI may be optimal. #ESMO21 #bcsm @OncoAlert

ErikaHamilton9's tweet photo. Lucia Del Mastro presents #GIM4- ph III of extended letrozole for adj post-meno pts after 2-3 yrs tam:

❇️ improved DFS by 5%

✴️ 4% improvement in OS

For post-meno pts that get tam upfront, 7-8 years total w/ AI may be optimal.

#ESMO21 #bcsm @OncoAlert https://t.co/ua58pwZGyr

0

23

7

1

0

Stephanie Graff, MD, FACP, FASCO @DrSGraff

almost 5 years ago

Dr. Lucia Del Mastro: extended letrozole improves DFS and overall survival. 🍬Takeaway: 7-8 years of adjuvant endocrine therapy may be the sweet spot! #ESMO21 #GIM4

DrSGraff's tweet photo. Dr. Lucia Del Mastro: extended letrozole improves DFS and overall survival.
🍬Takeaway: 7-8 years of adjuvant endocrine therapy may be the sweet spot! #ESMO21 #GIM4 https://t.co/ioli2PysM3

1

45

11

4

0

Matteo Lambertini, MD PhD @matteolambe

almost 5 years ago · Paris

Presented at #ESMO21 and now online in @TheLancetOncol by @delmastro_lucia from @UniGenova and @SanMartino_Ge results of the #GIM4 trial on extended adjuvant therapy with letrozole in postmenopausal patients with early #BreastCancer @myESMO @OncoAlert https://t.co/SNurYnccxq

0

17

5

0

Centrum Doskonalenia Nauczyciel w Lesznie @CDNLeszno

over 7 years ago

Miło nam poinformować, że uczeń z #Gim4 w Lesznie Adam Wojciechowski został nagrodzony w Konkursie UMWW "Polacy w świecie znani z działalności publicznej, misyjnej, naukowej, artystycznej i sportowej" Konkurs na terenie Leszna i okolic koordynowały placówki CDNLeszno i PBPLeszno